GlassScriptPhysician profile
Tobin Brett Tilley
NPI 1215910088
$846.44
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $27.76 · 2021: $207 · 2022: $60.43 · 2023: $191 · 2024: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $341.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $350.43 | 2019-2024 | Myday Contact Lens |
| Alcon Vision LLC | $207.31 | 2019-2024 | Total30 |
| Biotissue Holdings INC. | $72.90 | 2022-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $41.82 | 2019 | |
| Optos, INC. | $33.16 | 2019-2020 | |
| Rxsight INC | $31.95 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Allergan, INC. | $24.72 | 2021 | |
| Tearlab Corp | $18.57 | 2024 | Scoutpro Osmolarity System |
| Oyster Point Pharma, INC. | $18.55 | 2023 | Tyrvaya |
| Bausch & Lomb Americas INC. | $18.07 | 2023 | Infuse |
| Glaukos Corporation | $16.37 | 2019 | |
| Maculogix, INC. | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tobin Tilley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.